Poniard Pharmaceuticals, Inc. is a bio-pharmaceutical company, which focuses on the development and commercialization of oncology products. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2011-12-30. The firm focuses on the development and commercialization of oncology products to impact the lives of people with cancer. The company develops picoplatin, a platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. The firm has offices in San Francisco, California; and Seattle, Washington in United States.
PARD stock price ended at $0 on 星期二, after rising NaN%
On the latest trading day Jul 21, 2026, the stock price of PARD rose by NaN%, climbing from $0.00 to $0.00. Throughout the session, the stock experienced a volatility of NaN%, with prices fluctuating between a daily low of $0.00 and a high of $0.00. Alongside this price increase, trading volume also rose by 31 shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 100 shares were traded, amounting to a market value of approximately --.